{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T15:25:08Z","timestamp":1780154708553,"version":"3.54.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Acute myeloid leukemia (AML) is a common type of hematological malignancy in elderly people. Geriatricians have developed comprehensive geriatric assessment (CGA) methods for elderly patients; however, the tools used for CGA in AML are not uniform. Thus, we aimed to validate the instrumental activities of daily living (IADL) scales, age, comorbidities (Charlson Comorbidity Index), and albumin (IACA) index, which is a new tool for CGA, in elderly patients with AML.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients aged \u226560 years who had been diagnosed with AML were screened for eligibility. Among the IACA low-, intermediate-, and high-risk groups, continuous variables were compared using the Mann-Whitney <jats:italic toggle=\"yes\">U<\/jats:italic> test, and categorical variables were compared using <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> and Fisher exact tests. In addition, probabilities of overall survival (OS) were estimated using the Kaplan-Meier method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 21, 34, and 6 patients were categorized into IACA low-risk (0 point), intermediate-risk (1\u20132 points), and high-risk (\u22653 points) groups, respectively. The rates of relapse\/progression-related mortality were 23.8%, 58.8%, and 100.0% in the IACA low-, intermediate-, and high-risk groups, respectively (<jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a12.81, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001). The 2-year probabilities of OS were 47.7% (95% confidence interval [CI] 22.8%\u201372.6%) and 20.2% (95% CI 5.9%\u201334.5%) in the IACA low- and intermediate-risk groups, respectively (<jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a5.99, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.014), which were significantly higher than those in the high-risk group (low-risk [47.7% (95% CI 22.8%\u201372.6%)] <jats:italic toggle=\"yes\">vs.<\/jats:italic> high-risk [0], <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a20.80, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001; intermediate-risk [20.2% (95% CI 5.9%\u201334.5%)] <jats:italic toggle=\"yes\">vs.<\/jats:italic> high-risk [0], <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a7.56, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.006; respectively). In the IACA low-risk group, the 2-year probability of OS in patients receiving induction chemotherapy (50.8% [95% CI 24.1%\u201377.5%]) was significantly higher than that in those receiving best supportive care (0, <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a25.74, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>We suggest that the IACA index might be a simple and effective tool for comprehensive geriatric assessment in elderly AML patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000000645","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T09:32:18Z","timestamp":1578994338000},"page":"381-387","source":"Crossref","is-referenced-by-count":8,"title":["A new tool for comprehensive geriatric assessment in elderly patients with acute myeloid leukemia: a pilot study from China"],"prefix":"10.1097","volume":"133","author":[{"given":"Chun-Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Fei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"R1-20230813","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J Clin Oncol"},{"key":"R2-20230813","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1182\/blood-2011-12-379008","article-title":"Acute myeloid leukemia in the real world: why population-based registries are needed","volume":"119","author":"Juliusson","year":"2012","journal-title":"Blood"},{"key":"R3-20230813","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"R4-20230813","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","article-title":"How I treat the older patient with acute myeloid leukemia","volume":"125","author":"Ossenkoppele","year":"2015","journal-title":"Blood"},{"key":"R5-20230813","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"R6-20230813","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<395::AID-CNCR24>3.0.CO;2-W","article-title":"Validation of a multidimensional evaluation scale for use in elderly cancer patients","volume":"77","author":"Monfardini","year":"1996","journal-title":"Cancer"},{"key":"R7-20230813","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.leukres.2013.05.013","article-title":"Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes","volume":"37","author":"Sherman","year":"2013","journal-title":"Leuk Res"},{"key":"R8-20230813","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"R9-20230813","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3324\/haematol.2012.067892","article-title":"Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome","volume":"98","author":"Deschler","year":"2013","journal-title":"Haematologica"},{"key":"R10-20230813","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/asheducation-2016.1.339","article-title":"Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction","volume":"2016","author":"Rao","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R11-20230813","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1634\/theoncologist.2016-0260","article-title":"A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma","volume":"22","author":"Miura","year":"2017","journal-title":"Oncologist"},{"key":"R12-20230813","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1634\/theoncologist.2017-0361","article-title":"Validation and refinement of the age, comorbidities, and albumin index in elderly patients with diffuse large B-cell lymphoma: an effective tool for comprehensive geriatric assessment","volume":"23","author":"Liu","year":"2018","journal-title":"Oncologist"},{"key":"R13-20230813","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R14-20230813","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"R15-20230813","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"R17-20230813","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"R18-20230813","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-20230813","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1002\/cncr.24490","article-title":"A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy","volume":"115","author":"Tucci","year":"2009","journal-title":"Cancer"},{"key":"R20-20230813","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.clml.2015.03.004","article-title":"Prognostic effect of comorbidity indices in elderly patients with multiple myeloma","volume":"15","author":"Bila","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R21-20230813","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2015.1091933","article-title":"Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: results of the CLL9 trial of the German CLL study group","volume":"57","author":"Goede","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"R22-20230813","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14301","article-title":"Effect of intensive chemotherapy on physical, cognitive, and emotional health of older adults with acute myeloid leukemia","volume":"64","author":"Klepin","year":"2016","journal-title":"J Am Geriatr Soc"},{"key":"R23-20230813","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00432-006-0115-7","article-title":"Impairment in functional status and survival in patients with acute myeloid leukaemia","volume":"132","author":"Wedding","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"R24-20230813","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jgo.2015.10.182","article-title":"Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML)","volume":"7","author":"Tawfik","year":"2016","journal-title":"J Geriatr Oncol"},{"key":"R25-20230813","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22537","article-title":"Comorbidity is an independent predictor of complete remission in elderly patients receivinginduction chemotherapy for acute myeloid leukemia","volume":"109","author":"Etienne","year":"2007","journal-title":"Cancer"},{"key":"R26-20230813","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1182\/asheducation.V2012.1.74.3806844","article-title":"In elderly patients with AML, which patients should be considered fit or unfit for standardinduction therapy?","volume":"2012","author":"Swords","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"(Suppl 1)","key":"R27-20230813","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.clml.2011.02.003","article-title":"Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry","volume":"11","author":"Juliusson","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R28-20230813","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00277-015-2351-x","article-title":"Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States","volume":"94","author":"Medeiros","year":"2015","journal-title":"Ann Hematol"},{"key":"R29-20230813","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/S0140-6736(10)62105-8","article-title":"Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes","volume":"376","author":"Krug","year":"2010","journal-title":"Lancet"},{"key":"R30-20230813","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/17474086.2017.1382345","article-title":"The management and treatment of acute leukemias in the elderly population","volume":"10","author":"Thomas","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R31-20230813","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"N Engl J Med"},{"key":"R32-20230813","first-page":"53","article-title":"Decitabine in the treatment of acute myeloid leukemia in elderly patients","volume":"6","author":"Malik","year":"2014","journal-title":"Cancer Manag Res"},{"key":"R33-20230813","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"key":"R34-20230813","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of olderpatients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"R35-20230813","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Blood"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T09:01:40Z","timestamp":1691917300000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000000645","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]}}}